2-bromo-N-methoxy-N-methylthiazole-4-carboxamide | 888314-10-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-bromo-N-methoxy-N-methylthiazole-4-carboxamide
• 英文别名: 2-Bromo-N-methoxy-N-methylthiazole-4-carboxamide；2-bromo-N-methoxy-N-methyl-1,3-thiazole-4-carboxamide
• CAS: 888314-10-1
• 化学式: C₆H₇BrN₂O₂S
• 分子量: 251.104
• InChiKey: AYKXSQPCHDEZTL-UHFFFAOYSA-N

物化性质

• 沸点：
  364.9±15.0 °C(Predicted)
• 密度：
  1.674±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  70.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-bromo-N-methoxy-N-methylthiazole-4-carboxamide 在 二异丁基氢化铝 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 2-溴-4-醛基噻唑
  参考文献：
  名称：

  [EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
  [FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS MÉTHODES D'UTILISATION

  摘要：

  提供了用于治疗癌症的化合物以及治疗癌症的方法，包括向需要的受试者施用本文描述的化合物。

  公开号：

  WO2015003640A1
• 作为产物：
  描述：

  2-溴-4-噻唑羧酸 、 N-甲基-N-甲氧基胺盐酸盐 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 二氯甲烷 为溶剂， 生成 2-bromo-N-methoxy-N-methylthiazole-4-carboxamide
  参考文献：
  名称：

  [EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
  [FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS MÉTHODES D'UTILISATION

  摘要：

  提供了用于治疗癌症的化合物以及治疗癌症的方法，包括向需要的受试者施用本文描述的化合物。

  公开号：

  WO2015003640A1

文献信息

• Inducible nitric oxide synthase dimerization inhibitors
  申请人：Gahman C. Timothy

  公开号：US20060116515A1

  公开（公告）日：2006-06-01

  The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR 4 , N, NR 4 , S, and O; U is selected from the group consisting of CR 10 and N; V is selected from the group consisting of CR 4 and N; W and W′ are independently selected from the group consisting of CH 2 , CR 7 R 8 , NR 9 , O, N(O), S(O) q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.

  本发明涉及化合物和方法，用作一氧化氮合酶的抑制剂。本发明的某些化合物具有以下结构式： 其中T、X和Y分别选自CR 4 、N、NR 4 、S和O组成的群；U选自CR 10 和N组成的群；V选自CR 4 和N组成的群；W和W′分别选自CH 2 、CR 7 R 8 、NR 9 、O、N(O)、S(O) q 和C(O)组成的群；n、m和p分别是从0到5的整数；q为0、1或2；其他取代基如本文所定义。本发明的其他化合物具有如本文所定义的结构式。本文还公开了包含本发明化合物的药物组合物。
• THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
  申请人：Konteatis Zenon D.

  公开号：US20150018328A1

  公开（公告）日：2015-01-15

  Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

  提供了用于治疗癌症的化合物以及治疗癌症的方法，包括向需要的受试者施用本文所述的化合物。
• SYNTHESIS OF THERAPEUTICALLY ACTIVE COMPOUNDS
  申请人：Agios Pharmaceuticals, Inc.

  公开号：EP3686190A1

  公开（公告）日：2020-07-29

  Provided are methods for preparing a compound of formula (Ia): Wherein R1-R8 and A are as defined in the claims.

  提供了制备式 (Ia) 化合物的方法： 其中 R1-R8 和 A 如权利要求中定义。
• Therapeutically active compounds and their methods of use
  申请人：AGIOS PHARMACEUTICALS, INC.

  公开号：US10028961B2

  公开（公告）日：2018-07-24

  Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

  本发明提供了用于治疗癌症的化合物以及治疗癌症的方法，其中包括向有需要的受试者施用本文所述的化合物。
• Optimization of Novel 1-Methyl-1<i>H</i>-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber’s Pole Worm
  作者：Thuy G. Le、Abhijit Kundu、Atanu Ghoshal、Nghi H. Nguyen、Sarah Preston、Yaqing Jiao、Banfeng Ruan、Lian Xue、Fei Huang、Jennifer Keiser、Andreas Hofmann、Bill C. H. Chang、Jose Garcia-Bustos、Abdul Jabbar、Timothy N. C. Wells、Michael J. Palmer、Robin B. Gasser、Jonathan B. Baell

  DOI：10.1021/acs.jmedchem.8b01544

  日期：2018.12.13

  A phenotypic screen of a diverse library of small molecules for inhibition of the development of larvae of the parasitic nematode Haemonchus contortus led to the identification of a 1-methyl-1H-pyrazole-5-carboxamide derivative with an IC50 of 0.29 mu M. Medicinal chemistry optimization targeted modifications on the left-hand side (LHS), middle section, and right-hand side (RHS) of the scaffold in order to elucidate the structure-activity relationship (SAR). Strong SAR allowed for the iterative and directed assembly of a focus set of 64 analogues, from which compound 60 was identified as the most potent compound, inhibiting the development of the fourth larval (L4) stage with an IC50 of 0.01 mu M. In contrast, only 18% inhibition of the mammary epithelial cell line MCF10A viability was observed, even at concentrations as high as 50 mu M.